Bank of America Securities analyst Alec Stranahan maintained a Sell rating on Editas Medicine (EDIT – Research Report) yesterday and set a ...

CRISPR stock decline is influenced by Editas Medicine's struggles, but CRSP remains strong with FDA approval and strategic ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Editas Medicine (EDIT – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Yanan Zhu ...

Editas Medicine Inc (EDIT) stock saw a decline, ending the day at $1.16 which represents a decrease of $-0.10 or -7.94% from the prior close of $1.26. The stock opened at $1.24 and touched a low of $1 ...

Editas Medicine ( (EDIT) ) has provided an announcement. Editas Medicine announced new in vivo preclinical proof of concept data and outlined its strategic priorities and key milestones for 2025, ...

Nanomedicine is a branch of medicine that applies the knowledge and tools of nanotechnology to the prevention and treatment of disease. Nanomedicine involves the use of nanoscale materials ...

Editas Medicine Inc (EDIT) stock saw a decline, ending the day at $1.26 which represents a decrease of $-0.08 or -5.97% from the prior close of $1.34. The stock opened at $1.33 and touched a low of $1 ...

Intellia Therapeutics is starting off 2025 with a significant head count reduction as it tosses out pipeline assets to keep ...

We recently compiled a list of the Top 11 CRISPR Stocks to Invest In. In this article, we are going to take a look at where Editas Medicine, Inc. (NASDAQ:EDIT) stands against the other CRISPR stocks.

The business’s 50 day moving average is $2.37 and its 200 day moving average is $3.60. Editas Medicine, Inc. has a 12-month low of $1.16 and a 12-month high of $11.58. The stock has a market cap ...